India's fully integrated, innovation-led biopharmaceutical company spanning biosimilars, generics, novel biologics and contract research.
biocon.comCEO & Managing Director
Shreehas P Tambe
Executive Chairperson
Kiran Mazumdar-Shaw
CFO
Kedar Upadhye
Founded
1978
Industry
Biopharmaceuticals
Revenue (FY26)
₹16,927 Cr
Market Cap
₹71,755 CrListed on
NSE: BIOCON / BSE: 532523
Headquarters
Bengaluru, Karnataka, India
Website
biocon.comBiocon Limited is an Indian biopharmaceutical company founded in 1978 by Kiran Mazumdar-Shaw and headquartered in Bengaluru, Karnataka. It's listed on the NSE (BIOCON) and BSE (532523). The company operates across four business areas: biosimilars, research services through its subsidiary Syngene International, generics, and novel biologics, serving customers in more than 120 countries.
In FY26 Biocon reported consolidated sales of about ₹16,927 crore, with biosimilars contributing the largest share of revenue, followed by research services and generics. As of the data reviewed, the company carried a market capitalisation of roughly ₹71,755 crore. Its listed subsidiary Biocon Biologics is being fully integrated as a wholly owned subsidiary, creating a unified corporate structure.
The company underwent a leadership transition effective 1 April 2026. Shreehas P Tambe, previously CEO and Managing Director of Biocon Biologics, became CEO and Managing Director of Biocon Limited, and Kedar Upadhye was appointed Chief Financial Officer. Kiran Mazumdar-Shaw continues as Executive Chairperson. Outgoing CEO Siddharth Mittal moved to another leadership role within the Biocon Group.
Interview experience
Favorable
Interview difficulty
Medium
Interview process length
About a month
Practice real interview questions with Hyring's AI interviewer and get instant, structured feedback before the real thing.
Q: Questions related to Biochemistry and Microbiology
A: Expect fundamentals across biochemistry and microbiology, such as enzyme kinetics, protein structure, fermentation, sterility and microbial contamination control relevant to biopharma manufacturing.
Q: Why do you want to work at Biocon?
A: Connect Biocon's leadership in biosimilars and affordable biologics to your own interest in commercial strategy and global access to medicine.
Q: Describe a challenging scenario you have faced in business development and how you overcame it.
A: Use the STAR method: describe the Situation and Task, the Action you took, and the measurable Result, keeping it specific to a real deal or partnership.
Q: What do you consider when expanding a product portfolio?
A: Weigh unmet clinical need, market size, competitive intensity, regulatory pathway, manufacturing fit and expected return before adding a product.
Practice real interview questions with Hyring's AI interviewer and get instant, structured feedback before the real thing.
All experience levels
₹15,70,050/year
20 Salaries submitted
All experience levels
₹11,37,446/year
16 Salaries submitted
All experience levels
₹6,32,832/year
42 Salaries submitted
All experience levels
₹11,67,807/year
3 Salaries submitted
All experience levels
₹3,51,344/year
47 Salaries submitted
All experience levels
₹3,82,639/year
3 Salaries submitted
Benchmark your salary against thousands of data points and discover roles that match your experience.
Bengaluru, Karnataka • Full Time
Bengaluru, Karnataka • Full Time
Bengaluru, Karnataka • Full Time
Bengaluru, Karnataka • Full Time
Bengaluru, Karnataka • Full Time
Bengaluru, Karnataka • Full Time
Create an ATS-ready resume tailored to Biocon roles in minutes with Hyring's AI resume builder.
May 7, 2026
Biocon posts FY26 total income of Rs 17,270 crore, declares dividend
Biocon reported Q4FY26 total income of Rs 4,569 crore with EBITDA of Rs 1,073 crore and net profit before exceptional items of Rs 179 crore, taking FY26 total income to Rs 17,270 crore. The company recommended a final dividend of Re 0.50 per share and named Shreehas Tambe CEO and MD and Kedar Upadhye CFO.
#Earnings #FY26 #Dividend
View postApril 7, 2026
Biocon launches denosumab biosimilars Bosaya and Aukelso in the US
Biocon Biologics began US commercial sales of Bosaya, a biosimilar to Prolia, and Aukelso, a biosimilar to Xgeva, both denosumab biosimilars. Denosumab products generated about USD 5 billion in US sales in 2024.
#Biosimilars #FDA #Launch
View postFebruary 12, 2026
Biocon Q3FY26 revenue up 9% to Rs 4,173 crore, net profit at Rs 144 crore
Q3FY26 operating revenue rose 9% year on year to Rs 4,173 crore with EBITDA of Rs 951 crore and net profit of Rs 144 crore. Biosimilars grew on North American demand while generics climbed 24%.
#Earnings #Q3FY26 #Biosimilars
View postDecember 6, 2025
Biocon to fully integrate Biocon Biologics into a single entity
Biocon announced it would acquire the minority stakes in Biocon Biologics through a share swap, valuing the biosimilars business at USD 5.5 billion and making it a wholly owned subsidiary. The move simplifies the corporate structure across diabetes, oncology and immunology.
#Restructuring #Biosimilars #Corporate
View postApril 10, 2025
Biocon Biologics wins US FDA approval for Jobevne, its seventh US biosimilar
The FDA approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin, for multiple cancer types, marking Biocon Biologics' seventh biosimilar approved in the US. The company cited a development pipeline of 20 biosimilar assets.
#FDA #Biosimilars #Oncology
View postBiocon Limited is an Indian biopharmaceutical company. It operates across four business areas: biosimilars, research services through its subsidiary Syngene International, generics, and novel biologics, serving customers in more than 120 countries.
